Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year GuidanceReports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted ...

SHENZHEN, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services in China, recently showcased its flagship platforms, EngageLab and GPTBots.ai, at DXPO Fukuoka 2025 (October 10–11), Japan’s premier Sales & Marketing Digital Transformation Expo held at Marine Messe Fukuoka. The Company demonstrated how its innovative solutions help Japanese enterprises enhance efficiency, custo ...

收购交易核心条款 - ECGI控股公司签署具有约束力的意向书 以全股票交易方式收购RezyFi Inc 交易价值约为3000万美元[1] - ECGI将通过发行优先股收购RezyFi 100%的已发行股权 该交易为非现金交易 旨在维护股东价值[2] - 尽职调查完成并签署最终协议后 RezyFi将成为ECGI控股公司的全资子公司[2] 战略意义与业务协同 - 此次收购标志着ECGI战略性地进入金融科技行业[3] - 合并后的实体将利用人工智能驱动的贷款处理和区块链支持的碎片化抵押贷款投资 以简化贷款操作并提高效率[3] - 公司旨在创建一个融合机构级合规性与尖端数字金融基础设施的下一代抵押贷款平台[3] - 公司计划成为首批在合规平台上对抵押贷款进行代币化的企业之一 为投资者创造获取房地产支持收益产品的新机会[4] 管理层观点与技术整合 - ECGI总裁指出 此次收购将弥合传统抵押贷款与下一代金融技术之间的差距 结合RezyFi的全国性牌照和运营基础设施与ECGI的资本市场及技术专长具有巨大潜力[5] - RezyFi首席执行官表示 加入ECGI将加速其向技术驱动型抵押贷款平台的演变 合作实施人工智能和区块链解决方案将使贷款对投资者和借款人更快、更智能、更易获得[5] - 公司将在后续发布中分享技术整合路线图的更多更新 包括引入专业的人工智能和区块链开发团队 这些举措预计将开辟新的收入来源[5] 公司背景与投资组合 - ECGI控股公司是一家技术驱动的投资和开发公司 专注于构建具有可持续长期收入模式的技术驱动型创新企业[6] - 公司的投资组合和战略利益涵盖人工智能、金融科技、时尚科技和体验式酒店等高增长行业[6] - 公司当前的投资和合作伙伴包括Entrepreneur Ventures Fund I TCA Venture Group AuraChat ai Payday Fantasy TrueToForm Pacific Saddlery以及Vintner's Caldera Ranch等[7]

VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has secured a $30 million funding commitment from Yorkville Advisors Global. Under the terms of the ...

November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the approval of a Clinical Trial Application (CTA) by the European Medicines Agen ...

-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ women’s health mission -- ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical ...

BEIJING, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced that representatives from the Chinese Academy of International Trade and Economic Cooperation under the Ministry of Commerce (“CAITEC”) and the Commercial Circulation Promotion Division of the Chaoyang ...

Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populationsVALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced two podium presentations at the 2025 Southern Region Burn Conference (SRBC) that collectively underscore the clinical and economic value of the ...

TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that it has signed a new contract with a leading biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial of a novel psychiatric medicine. This represents continued industry p ...

TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed its final short form base shelf prospectus (the “Prospectus”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when need ...